U.S. Artificial Intelligence In Healthcare Market (2025 - 2033)

U.S. Artificial Intelligence In Healthcare Market Summary

The U.S. Artificial Intelligence in healthcare market size was estimated at USD 13.26 billion in 2024 and is projected to grow at a CAGR of 36.76% from 2025 to 2033. Robust digital health infrastructure and investments in AI technology, the growing prevalence of chronic diseases, and the increasing demand for personalized and remote healthcare solutions are factors driving market growth.

In addition, supportive government initiatives, a shortage of healthcare professionals, and the growing need for operational efficiency are some other factors propelling market growth further. For instance, in October 2024, Amazon One Medical launched AI tools integrated into its proprietary electronic health record system, 1Life, to enhance patient care and reduce clinician administrative burden.

The increasing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, coupled with a rapidly aging population, is significantly driving the demand for AI-enabled healthcare solutions in the United States. For instance, according to the CDC, 6 in 10 Americans are affected by at least one chronic disease. In addition, the aging demographic is projected to grow substantially, with the Population Reference Bureau estimating that by 2050, the population aged 65 or older is expected to be 82 million. This demographic shift presents an opportunity to enhance long-term care, continuous health monitoring, and effective disease management, where AI is potentially significant.

Furthermore, the country's healthcare infrastructure is characterized by an advanced digital health ecosystem, widespread adoption of electronic health records (EHR), extensive data repositories, and cutting-edge health IT systems. Major health tech firms have made significant investments in healthcare AI solutions, while startups continue to attract substantial venture capital funding. For instance, in February 2025, Harrison.ai, a global health tech company, expanded its U.S. footprint with USD 112 million in Series C funding to advance its AI-powered medical diagnostic and workflow solutions.

Moreover, the increasing adoption of telehealth solutions for remote patient monitoring drives market growth further. AI systems enhance virtual care by automating patient data analysis, facilitating real-time decision-making, and improving patient engagement outside traditional clinical settings. For instance, in December 2024, VSee Health, anAI-powered telehealth platform provider, partnered with Tele911 to create the first virtual emergency department. The aim is to reduce ER overcrowding and address emergency medical services (EMS) staffing shortages. Such initiatives enable healthcare delivery to be more accessible and convenient, especially for patients in remote or underserved areas. Thus, they increase the demand for AI-powered telehealth solutions and contribute to market growth.

Recent Developments in the U.S. AI in Healthcare Market Landscape

Market Concentration & Characteristics

The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The X-axis represents the level of market concentration, ranging from low to high. The Y-axis represents various market characteristics, including industry competition, degree of innovation, level of mergers & acquisition activities, regulatory impact, and regional expansion. The U.S. artificial intelligence (AI) in healthcare market is fragmented, with the presence of several emerging solution providers dominating the market. The degree of innovation, the level of partnerships & collaborations, and the impact of regulations on industry are high. The regional expansion of the industry is moderate.

The degree of innovation in the market is high, driven by rapid advancements in machine learning, natural language processing, and cloud-based AI tools. Companies continuously develop intelligent solutions for diagnostics, clinical decision support, drug discovery, personalized treatments, and workflow automation. Significant innovations include predictive analytics for disease detection and virtual health platforms integrated with AI algorithms. For instance, in June 2024, Florida-based CCS launched PropheSee, an AI-powered predictive model designed to improve therapy adherence for people with diabetes who use continuous glucose monitors (CGMs).

The industry is experiencing a high level of partnerships & collaborations undertaken by several key players. This is due to the desire to gain a competitive advantage in the industry, enhance technological capabilities, and consolidate in a rapidly growing market. For instance, in January 2025, NVIDIA partnered with IQVIA, Illumina, Mayo Clinic, and Arc Institute to enhance drug discovery, advance genomic research, and drive innovation in healthcare through agentic and generative AI.

Regulations, such as HIPAA, establish standards for safeguarding patient data privacy and security. Compliance with these regulations is crucial for AI applications in healthcare to ensure the safe and secure handling of patient information, reducing the risk of data breaches and unauthorized access. Supportive policies from agencies such as the FDA, including accelerated approvals for AI-based medical devices and software, encourage innovation while ensuring patient safety.

The level of regional expansion in the industry is moderate, driven by an increasing customer base for solutions to streamline healthcare operations, especially in rural areas. The increasing prevalence of diseases exerts pressure on healthcare providers, diagnostic centers, and pharmacies, creating opportunities for enhanced patient engagement solutions to reduce administrative burden.

Case Study: Accelerating Drug Discovery at Nimbus Therapeutics with AWS

Nimbus Therapeutics, a biotechnology company specializing in the design of selective small molecules for treating cancer, autoimmune disorders, and metabolic diseases, sought to enhance its drug discovery process. By integrating machine learning (ML) and automating operational workflows, Nimbus aimed to expedite the identification and development of promising drug candidates. To achieve this, the company collaborated with Amazon Web Services (AWS) to implement a robust ML operations (MLOps) pipeline using Amazon SageMaker.

Component Insights

Based on components, the software solution segment dominated the market with the largest revenue share of 44.19% in 2024. This growth is attributed to the increasing demand for advanced AI-based platforms that support clinical decision-making, medical imaging, predictive analytics, and workflow automation. In addition, ongoing innovation in cloud-based AI tools, NLP, and machine learning algorithms tailored for U.S. healthcare regulations and infrastructure further strengthens the software segment’s dominance in the market. For instance, in February 2024, SpinSci Technologies, a cloud patient engagement solutions provider, partnered with Webex by Cisco, a prominent collaboration technology provider, to create a comprehensive patient engagement platform tailored for Webex Contact Center and Webex Connect.

The services segment is anticipated to grow at the fastest CAGR during the forecast period due to the rising demand for AI integration, deployment, training, and maintenance across U.S. healthcare institutions. As hospitals and clinics adopt complex AI systems, they increasingly rely on specialized service providers to ensure smooth implementation and ongoing technical support. In addition, the shift towards value-based care and digital transformation requires continuous upgrades and customization, boosting demand for consulting and managed services.

Application Insights

Based on application, the robot-assisted surgery segment dominated the market with the largest revenue share of 13.50% in 2024. The rising adoption of AI-powered robotic systems that enhance surgical precision, reduce complications, and improve patient outcomes drives the segment's growth. Moreover, the increasing number of minimally invasive procedures, coupled with a growing geriatric population requiring complex surgeries, has accelerated the use of robotic assistance.

For instance, in July 2024, Medtronic launched Touch Surgery Live Stream technology, an AI-powered robotic and laparoscopic surgery platform. The platform features 14 new AI algorithms that enhance post-operative analysis by providing surgical workflow, instrument, and anatomy detection, delivering actionable insights from surgical videos.

The fraud detection segment is anticipated to grow at the fastest CAGR over the forecast period. The increasing penetration of health insurance and the rising number of fraud cases in the healthcare industry are factors driving segment growth. In addition, the growing focus on curbing healthcare costs and the technological advancements to launch advanced analytical techniques are also expected to fuel segment growth.

Technology Insights

Based on technology, the machine learning segment dominated the market with the largest revenue share of 35.75% in 2024. Machine learning algorithms are extensively used for disease prediction, medical imaging analysis, patient risk assessment, and treatment recommendation systems. The increasing availability of large healthcare datasets and advancements in computing power and cloud infrastructure have accelerated the deployment of ML models in healthcare. The growing investments in precision medicine and clinical research further support the adoption of machine learning.

Context-aware computing segment is projected to grow at the fastest CAGR over the forecast period. This growth is attributed to its ability to deliver personalized and adaptive healthcare solutions by analyzing real-time contextual data such as patient location, behavior, medical history, and environment. The increasing focus on patient-centric care, remote monitoring, and smart healthcare infrastructure is driving demand for context-aware technologies. These systems enhance clinical decision-making, reduce errors, and improve patient engagement.

End Use Insights

Based on end use, the pharmaceutical & biotechnology companies segment dominated the market with a share of 30.22% in 2024. This growth is attributed to the increasing use of AI in drug discovery, clinical trial optimization, and personalized medicine development. U.S.-based pharma and biotech firms are leveraging AI to accelerate R&D, reduce time-to-market, and improve the accuracy of candidate drug identification.

The patients segment is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of AI-powered tools that enhance patient engagement, self-care, and health monitoring. Additionally, the growing awareness of digital health technologies, coupled with the widespread utilization of smartphones, wearable devices, and health applications, empowers patients to take a more proactive role in managing their health. AI-driven chatbots, virtual assistants, and personalized health insights improve access to chronic disease management and mental health support, driving rapid growth in this segment.

Key U.S. Artificial Intelligence in Healthcare Companies Insights

Key players operating in the U.S. Artificial Intelligence in healthcare market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In June 2025, Eko Health secured USD 41 million in funding in the U.S. to scale its AI-driven technology for early detection of heart and lung diseases, aiming to improve diagnostic accuracy and patient care.

"Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere. Just as Ring transformed doorbells into home security systems, Eko has reinvented the world’s most ubiquitous medical tool into a powerful early disease detection platform, creating the world’s largest install base of professional AI-enabled cardiology devices."

-Connor Landgraf, CEO and co-founder of Eko Health.

• In April 2025, BD launched the HemoSphere Alta system, an advanced surgical monitoring platform featuring AI-powered programs to predict blood pressure changes during critical procedures.

• In March 2025, athenahealth expanded its AI documentation technology in the U.S. by partnering with Abridge to enhance clinical note accuracy and streamline healthcare provider workflows.

“Writing notes is something that has been a pain point for physicians since time began. Artificial intelligence has gotten to the point now where it can listen to a provider-patient conversation and generate a note for the physician.”

-Paul Brient, chief product officer at Athenahealth

• In March 2025, Microsoft launched Dragon Copilot in the U.S., the healthcare industry’s first unified voice AI assistant that streamlined clinical documentation, automated tasks, and enhanced clinician information access.

“At Microsoft, we have long believed that AI has the incredible potential to free clinicians from much of the administrative burden in healthcare and enable them to refocus on taking care of patients. With the launch of our new Dragon Copilot, we are introducing the first unified voice AI experience to the market, drawing on our trusted, decades-long expertise that has consistently enhanced provider wellness and improved clinical and financial outcomes for provider organizations and the patients they serve.”

-Joe Petro, corporate vice president of Microsoft Health and Life Sciences Solutions and Platforms.

• In January 2025, General Catalyst and LinkedIn cofounder Reid Hoffman launched Manas AI, an AI-driven drug discovery platform. The platform uses proprietary AI, computational chemistry, and molecular docking to accelerate drug discovery, initially targeting aggressive cancers. Manas AI partners with Microsoft Azure for scalable cloud-based drug development.

• In September 2024, EDAP TMS S.A. and Avenda Health launched an AI-assisted Focal One robotic HIFU procedure for prostate cancer treatment. Utilizing Avenda's FDA-cleared Unfold AI technology, these procedures enable personalized, patient-specific cancer care by creating 3D cancer maps, enhancing surgical precision, and minimizing damage to healthy tissue.

U.S. Artificial Intelligence In Healthcare Market